Thrivent Financial for Lutherans Reduces Holdings in Enovis Co. (NYSE:ENOV)

Thrivent Financial for Lutherans cut its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 33.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 159,838 shares of the company's stock after selling 80,597 shares during the period. Thrivent Financial for Lutherans owned approximately 0.28% of Enovis worth $7,014,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. UMB Bank n.a. grew its holdings in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after purchasing an additional 437 shares during the period. Pinnacle Bancorp Inc. lifted its position in Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after buying an additional 300 shares during the last quarter. FMR LLC boosted its stake in Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after buying an additional 484 shares during the period. XTX Topco Ltd purchased a new position in Enovis during the third quarter worth about $217,000. Finally, Legacy Capital Wealth Partners LLC acquired a new stake in shares of Enovis during the fourth quarter valued at about $228,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC decreased their price target on Enovis from $65.00 to $64.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th.

Remove Ads

Enovis Stock Down 0.8 %

Enovis stock traded down $0.29 during mid-day trading on Thursday, reaching $38.89. 514,559 shares of the company's stock were exchanged, compared to its average volume of 673,462. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis Co. has a twelve month low of $35.14 and a twelve month high of $62.79. The company has a market cap of $2.22 billion, a P/E ratio of -17.76 and a beta of 2.05. The company has a fifty day moving average of $42.38 and a 200-day moving average of $43.41.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $560.98 million for the quarter, compared to analysts' expectations of $555.14 million. Sell-side analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.